UPDATE 1-FDA approves Boehringer-Lilly drug for type-2 diabetes patients

February 2, 2015 2:36 PM

2 0

Feb 2 (Reuters) - The U.S. Food and Drug Administration approved a drug developed by Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc to improve blood sugar control in type-2 diabetes patients, the companies said.

The drug, Glyxambi, is a once-daily tablet that combines empagliflozin and linagliptin, commonly prescribed diabetes medications which are manufactured by Lilly and privately held Boehringer.

Read more

To category page